Antimicrobial activity of the novel polymyxin derivative nab739 tested against gram-negative pathogens

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 636-639

  Vaara, Martti ^a,b   Sader, Helio S ^c   Rhomberg, Paul R ^c   Jones, Ronald N ^c   Vaara, Timo ^a  

^a Technopolis   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c JMI LABORATORIES   (United States)

Author keywords

Acinetobacter spp; Escherichia coli; Klebsiella pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT; NAB 739; POLYMYXIN B; POLYMYXIN DERIVATIVE; UNCLASSIFIED DRUG;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL LOAD; BACTERIUM ISOLATE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 84873579983     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks438     Document Type: Article

References (13)

1. Al-Hasan MN, Eckel-Passow JE, Baddour LM. Impact of healthcareassociated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gramnegative BSI. Eur J Clin Microbiol Infect Dis 2012; 31: 1163-71.
2. Kollef MH, Zilberberg MD, Shorr AF et al. Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect 2011; 62: 130-5.
3. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009; 48: 1729-31.
4. Vaara M. Polymyxins and their novel derivatives. Curr Opin Microbiol 2010; 13: 574-81.
5. Vaara M, Fox J, Loidl G et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008; 52: 3229-36.
6. Mingeot-Leclercq MP, Tulkens PM, Denamur S et al. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 2012; 35: 248-52.
7. Vaara M, Siikanen O, Apajalahti J et al. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J Antimicrob Chemother 2010; 65: 942-5.
8. Vingsbo Lundberg C, Vaara T, Frimodt-Møller N et al. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J Antimicrob Chemother 2010; 65: 981-5.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
10. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-4.
11. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
12. Vaara M. Increased outer membrane resistance to ethylenediamine tetraacetate and cations in novel lipid A mutants. J Bacteriol 1981; 148: 426-34.
13. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992; 56: 395-411.